-
★
COVID-19: Pneumologen raten nach Negativstudien weiter von inhalativen Steroiden ab
(Hinzugefügt: 01.12.2021 um 17:58 Uhr)
https://www.aerzteblatt.de/nachrichten/129595/COVID-19-Pneumologen-raten-nach-Negativstudien-weiter-von-inhalativen-Steroiden-ab
-
★
The use of inhaled corticosteroids in early-stage COVID-19
(Hinzugefügt: 24.08.2021 um 16:56 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01809-2/fulltext
-
★
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
(Hinzugefügt: 10.04.2021 um 05:38 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00160-0/fulltext
-
Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients
(Hinzugefügt: 10.04.2023 um 14:38 Uhr)
https://www.nature.com/articles/s41598-023-31544-5
-
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
(Hinzugefügt: 27.05.2022 um 08:04 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00088-1/fulltext
-
Wie Kortikosteroide bei Covid-19 wirken
(Hinzugefügt: 26.04.2022 um 13:56 Uhr)
https://medical-tribune.ch/10104130/2022/wie-kortikosteroide-bei-covid-19-wirken/
-
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group
(Hinzugefügt: 29.03.2022 um 10:26 Uhr)
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00092-X/fulltext
-
Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality
(Hinzugefügt: 11.03.2022 um 10:43 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789710
-
Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19
(Hinzugefügt: 17.02.2022 um 07:06 Uhr)
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786012
-
Is Methylprednisolone Better than Dexamethasone for Severe COVID-19?
(Hinzugefügt: 17.02.2022 um 06:59 Uhr)
https://www.jwatch.org/na53560/2021/06/01/methylprednisolone-better-dexamethasone-severe-covid-19
-
Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19
(Hinzugefügt: 19.11.2021 um 15:34 Uhr)
https://www.nature.com/articles/s41591-021-01576-3
-
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia
(Hinzugefügt: 25.10.2021 um 07:32 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2785529
-
Glucocorticoid Dose in COVID-19 Lessons for Clinical Trials During a Pandemic
(Hinzugefügt: 25.10.2021 um 07:32 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2785531
-
Association of Serum Ferritin Levels and Methylprednisolone Treatment With Outcomes in Nonintubated Patients With Severe COVID-19 Pneumonia
(Hinzugefügt: 18.10.2021 um 09:46 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784632
-
High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-related Acute Respiratory Distress Syndrome: A Multicenter and Randomized Open-label Clinical Trial
(Hinzugefügt: 22.09.2021 um 10:27 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.15.21263597v1
-
Können Kortikosteroide die COVID-19-Therapie unterstützen?
(Hinzugefügt: 28.08.2021 um 13:35 Uhr)
https://www.aerzteblatt.de/nachrichten/126686/Koennen-Kortikosteroide-die-COVID-19-Therapie-unterstuetzen
-
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
(Hinzugefügt: 14.08.2021 um 09:15 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01744-X/fulltext
-
Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
(Hinzugefügt: 06.08.2021 um 10:50 Uhr)
https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_final.pdf
-
SARS-CoV-2: Asthmaspray mit Budesonid verhindert schwere Verläufe
(Hinzugefügt: 10.04.2021 um 12:07 Uhr)
https://www.aerzteblatt.de/nachrichten/121073/SARS-CoV-2-Asthmaspray-mit-Budesonid-verhindert-schwere-Verlaeufe
-
Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom
(Hinzugefügt: 10.04.2021 um 12:06 Uhr)
https://www.mdpi.com/2077-0383/10/8/1607
-
Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19
(Hinzugefügt: 10.04.2021 um 05:41 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00171-5/fulltext
-
Impact of corticosteroids in hospitalised COVID-19 patients
(Hinzugefügt: 04.04.2021 um 17:25 Uhr)
https://bmjopenrespres.bmj.com/content/8/1/e000766
-
COVID treatment developed in the NHS saves a million lives
(Hinzugefügt: 23.03.2021 um 15:45 Uhr)
https://www.england.nhs.uk/2021/03/covid-treatment-developed-in-the-nhs-saves-a-million-lives/
-
Repeated pulses of methyl-prednisolone in Adults Hospitalized with COVID-19 pneumonia and acute respiratory distress syndrome: A preliminary before-after study (CortiCOVID study)
(Hinzugefügt: 23.03.2021 um 10:02 Uhr)
https://www.sciencedirect.com/science/article/pii/S2659663621000059
-
COVID-19 and inhaled corticosteroids—another piece in an expanding puzzle
(Hinzugefügt: 05.03.2021 um 06:49 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00076-X/fulltext
-
Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?
(Hinzugefügt: 17.02.2021 um 14:49 Uhr)
https://www.tandfonline.com/doi/full/10.1080/17512433.2021.1888714
-
Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
(Hinzugefügt: 11.02.2021 um 12:36 Uhr)
https://www.nature.com/articles/s41467-021-21134-2
-
Methylprednisolone or Dexamethasone, Which One Is the Superior Corticosteroid in the Treatment of Hospitalized COVID-19 Patients: A Triple-Blinded Randomized Controlled Trial
(Hinzugefügt: 02.02.2021 um 09:58 Uhr)
https://www.researchsquare.com/article/rs-148529/v1
-
Dexamethason – EMA befürwortet Anwendung bei COVID-19
(Hinzugefügt: 17.01.2021 um 18:10 Uhr)
https://www.arznei-telegramm.de/html/2020_09/2009071_01.html
-
The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients with COVID-19
(Hinzugefügt: 06.01.2021 um 08:33 Uhr)
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(21)00002-4
-
Dexamethasone Vs. COVID-19: An Experimental Study in Line with the Preliminary Findings of a Large Trial
(Hinzugefügt: 18.12.2020 um 10:24 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33332726/
-
RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment
(Hinzugefügt: 02.12.2020 um 09:53 Uhr)
https://www.recoverytrial.net/news/recovery-trial-shortlisted-for-the-national-project-awards-2020-special-covid-19-response-category
-
Corticosteroids are associated with increased survival in elderly presenting severe SARS-Cov2 infection
(Hinzugefügt: 14.11.2020 um 11:06 Uhr)
https://www.medrxiv.org/content/10.1101/2020.11.10.20226886v1
-
Early, low-dose, short-term methylprednisolone decreased the mortality in critical COVID-19 patients
(Hinzugefügt: 09.11.2020 um 07:05 Uhr)
https://www.journalofinfection.com/article/S0163-4453(20)30696-4/fulltext
-
Dexmethason
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://journals.iucr.org/m/issues/2020/06/00/be5285/index.html
-
Dexmethason
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30503-8/fulltext
-
Dexamethasone in hospitalised patients
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30503-8/fulltext
-
Dexmethason
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.n-tv.de/panorama/Dexamethason-wird-Covid-19-Medikament-article22046316.html
-
Dexmethason/ Methylprednisolon
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.medrxiv.org/content/10.1101/2020.10.06.20171579v1